PDF herunterladen
CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(01): 65-68
DOI: 10.4103/wjnm.WJNM_37_19
Case Report

Rapid progression of carcinoma en cuirasse breast dermal metastases on 18F-fludeoxyglucose positron emission tomography–computed tomography

Colin Raymond Young
Department of Radiology, Yale New Haven Hospital, New Haven, CT, USA
,
Mallini Harigopal
1   Department of Pathology, Yale New Haven Hospital, New Haven, CT, USA
,
Darko Pucar
Department of Radiology, Yale New Haven Hospital, New Haven, CT, USA
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Cancer in the dermis of the breast has a poor prognosis. The breast dermis can become malignantly involved primarily in inflammatory breast cancer, through the direct extension of locally advanced breast cancer, or metastatically from an underlying breast mass or a distant primary malignancy (e.g., gastric adenocarcinoma). Breast dermal metastases have the shortest median survival among them. Breast dermal metastases are classified into eight clinicohistopathologic groups, one of which is carcinoma en cuirasse. We present a case of a 52-year-old female with a history of invasive ductal carcinoma, Stage IIIC (pT2N3a), treated with lumpectomy, axillary node dissection, and chemoradiation therapy that recurred as carcinoma en cuirasse breast dermal metastases. Through 18F-fludeoxyglucose positron emission tomography–computed tomography (18F-FDG PET-CT) and clinical images, the case illustrates the rapid progression and devastating consequences of carcinoma en cuirasse breast dermal metastases over a 4-month period despite optimal therapy. Furthermore, the case emphasizes the sensitivity of 18F-FDG PET-CT to detect pathology in the breast dermis. Finally, the case highlights the crucial role that nuclear medicine physicians play in helping clinical colleagues differentiate between the various breast dermal malignant manifestations and benign mastitis, a common confounder in postradiation patients.

Keywords

18F-fludeoxyglucose positron emission tomography–computed tomography - breast dermal metastases - carcinoma en cuirasse - inflammatory breast cancer - locally advanced breast cancer

Financial support and sponsorship

Nil.




Publikationsverlauf

Eingereicht: 18. Mai 2019

Angenommen: 01. Juli 2019

Artikel online veröffentlicht:
19. April 2022

© 2020. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:290-303.
  • 2 Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, et al. What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: A multidisciplinary approach. Radiographics 2013;33:2003-17.
  • 3 Garg PK, Prakash G. Current definition of locally advanced breast cancer. Curr Oncol 2015;22:e409-10.
  • 4 Schwartz RA. Histopathologic aspects of cutaneous metastatic disease. J Am Acad Dermatol 1995;33:649-57.
  • 5 Afiya S, Singh J. Carcinoma en cuirasse with zosteriform metastasis-a rare presentation of breast carcinoma. J Med Surg Pathol 2017;1:1-3.
  • 6 Perez-Pinera P, Chang Y, Deuel TF. Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment, and activation of stromal fibroblasts. Cell Cycle 2007;6:2877-83.
  • 7 Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, et al. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 2001;61:2361-4.
  • 8 Tsukamoto K, Ito N, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, et al. Allelic loss on chromosome 1p is associated with progression and lymph node metastasis of primary breast carcinoma. Cancer 1998;82:317-22.
  • 9 Calaf GM, Echiburú-Chau C, Zhao YL, Hei TK. BigH3 protein expression as a marker for breast cancer. Int J Mol Med 2008;21:561-8.
  • 10 Ochiai A, Akimoto S, Shimoyama Y, Nagafuchi A, Tsukita S, Hirohashi S, et al. Frequent loss of alpha catenin expression in scirrhous carcinomas with scattered cell growth. Jpn J Cancer Res 1994;85:266-73.
  • 11 Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program at the national cancer institute. J Natl Cancer Inst 2005;97:966-75.
  • 12 Schoenlaub P, Sarraux A, Grosshans E, Heid E, Cribier B. Survival after cutaneous metastasis: A study of 200 cases. Ann Dermatol Venereol 2001;128:1310-5.
  • 13 Mahore SD, Bothale KA, Patrikar AD, Joshi AM. Carcinoma en cuirasse: A rare presentation of breast cancer. Indian J Pathol Microbiol 2010;53:351-8.
  • 14 Savatard L. Cancer en cuirasse. Br J Dermatol Syph 1943;55:31-9.
  • 15 Mordenti C, Peris KM, Fargnoli C, Cerroni L, Chimenti S. Cutaneous metastatic breast carcinoma. Acta Dermatovenerol 2000;9:143-8.
  • 16 Tung L, Stone EC, Bhasin M, Sheth S, Nelson M, Sheth PA, et al. Breast carcinoma en cuirasse as a natural progression of untreated breast cancer. Case Stud Surg 2015;2:46-8.
  • 17 Win AZ, Aparici CM. Carcinoma en cuirasse from recurrent breast cancer seen on FDG-PET/CT. J Clin Imaging Sci 2015;5:35.